Generic Name: histrelin
Drug Class: Hormone Therapy Medications
Company: Endo Pharmaceuticals
Approval Status: Approved
Generic Version Available: No
Drug Indication
Vantas is a GnRH agonist approved for palliative treatment of advanced prostate cancer.
General Info
Testosterone and other male hormones (androgens) stimulate prostate cancer growth. Gonadotropin-releasing hormone (GnRH) agonists, also known as luteinizing hormone-releasing hormone (LHRH) agonists, block signals in the brain that direct the testicles to produce testosterone. Testosterone levels go up briefly (known as a flare) before falling to very low levels.
Dosage
Dosing Info:
Vantas is a long-acting implant, inserted under the skin of the upper arm, that lasts for a year.
Side Effects
Common side effects include fatigue, hot flashes and mild reactions at the implant site. Medications that lower testosterone may lead to reduced sexual desire, erectile dysfunction and shrinkage of the testicles. Potential serious side effects include increased risk of diabetes and cardiovascular disease.
For More Info: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021732s015lbl.pdf
Co-Pay Program Info: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021732s015lbl.pdf
Patient Assistance Program Info: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021732s015lbl.pdf
Last Reviewed: September 19, 2018
